Table 1, Cost Comparison Table of Biologic Treatments for Rheumatoid Arthritis in Adult Patients - Pharmacoeconomic Review Report: sarilumab (Kevzara)

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pharmacoeconomic Review Report: sarilumab (Kevzara) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May.

Cover of Pharmacoeconomic Review Report: sarilumab (Kevzara)

Pharmacoeconomic Review Report: sarilumab (Kevzara) [Internet].

Show details

Contents

Table 1Cost Comparison Table of Biologic Treatments for Rheumatoid Arthritis in Adult Patients

Comparators	Strength	Dose Form	Price ($)	Recommended Dose	Annual Drug Cost ($)
Sarilumab (Kevzara)	150 mg/1.14 mL 200 mg/1.14 mL	Pre-filled syringe	700.0000^a	200 mg SC every two weeks	18,200
Abatacept SC (Orencia)	125 mg/mL	Pre-filled syringe	366.1000^b	125 mg weekly^c	19,037
Abatacept IV (Orencia)	250 mg/15 mL	Vial	490.0500^b	Patients < 60 kg: 500 mg Patients 60 to 100 kg: 750 mg Patients > 100 kg: 1,000 mg 500 to 1,000 mg at weeks 0, 2, and 4 then every 4 weeks	Year 1: 20,582 Thereafter: 19,112
Adalimumab SC (Humira)	40 mg/0.8 mL	Pre-filled syringe or pen	769.9700	40 mg every other week	20,019
Anakinra (Kineret)	100 mg	Pre-filled syringe	48.0571	100 mg daily	17,493
Certolizumab pegol (Cimzia)	200 mg/mL	Pre-filled syringe	664.5100	400 mg at weeks 0, 2 and 4 then 200 mg every 2 weeks	Year 1: 19,271 Thereafter: 17,277
Etanercept (Enbrel)	25 mg	Vial	202.9300	50 mg weekly or two 25 mg doses on same day every week or every 3 or 4 days	21,105
Etanercept (Enbrel)	50mg/mL	Pre-filled syringe or auto-injector	405.9850		21,111
Entanercept (Brenzys)	50 mg/mL	Pre-filled syringe	305.0000^d	50 mg weekly	15,860
Golimumab SC (Simponi)	50 mg/0.5 mL	Pre-filled syringe or auto-injector	1,555.17	50 mg monthly	18,662
Golimumab IV (Simponi)	50 mg/4 mL	Vial	849.5000^b	2 mg/kg at weeks 0 and 4, then every 8 weeks thereafter	Year 1:17,829 Thereafter: 16,565
Infliximab (Remicade)	100 mg	Vial	987.5600	3 mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter Depending on clinical response, dose can be increased to 10 mg/kg and/or up to every four weeks	Year 1: 23,701 Thereafter: 19,257 10 mg/kg every 4 weeks: $102,706 annually
Infliximab (Inflectra)	100 mg	Vial	525.0000		Year 1: 12,600^b Thereafter: 10,238^b 10 mg/kg every 4 weeks: $54,600 annually¹⁵
Rituximab (Rituxan)	100 mg/10 mL 500 mg/50 mL	Vial	466.3200 2,331.61	A course consists of 1,000 mg infusions at weeks 0 and 2. Reassess for retreatment at week 26, no sooner than 16 weeks after previous	18,653 assumes 2 courses Per course: 9,326
Tocilizumab SC (Actemra)	162 mg/0.9 mL	Pre-filled syringe	355.0000	Patients < 100 kg: 162 mg SC every two weeks, increasing to weekly based on clinical response. Patients ≥ 100 kg: 162 mg SC weekly	Every two weeks: 9,230 Weekly: 18,460
Tocilizumab IV (Actemra)	80 mg/4 mL 200 mg/10mL 400 mg/20 mL	Vial	180.8100 452.0300 904.0600	4 mg/kg every 4 weeks followed by an increase to 8 mg/kg based on clinical response	4 mg/kg: 10,577^b 8 mg/kg: 17,629^b
Tofacitinib (Xeljanz)	5 mg	Tablet	23.5585	5 mg p.o. twice daily	17,151

: IV = intravenous; p.o. = orally; SC = subcutaneous.
a: Manufacturer’s submitted price.
b: Saskatchewan Formulary list price (January 2017).
c: Abatacept-naive patients require a single weight-based loading dose of 500, 750, or 1,000 mg intravenous abatacept, with weekly SC injections to start within one day thereafter, not included in cost.
d: IMS Quintiles Delta PA wholesale price (January 2017), also the price submitted to the CDR.²³
: Source: Ontario Drug Benefit Formulary or Exceptional Access Program (January 2017) list prices unless otherwise indicated. Patient weight assumed to be 75 kg. Excess medication in vials is assumed wasted. Annual period assumes 52 weeks, 26 x 2 weeks, 13 x 4 weeks, or 364 days per year.

From: Executive Summary

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Contents

Views

Cite this Page
Pharmacoeconomic Review Report: sarilumab (Kevzara) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May. Table 1, Cost Comparison Table of Biologic Treatments for Rheumatoid Arthritis in Adult Patients.
PDF version of this title (927K)

Other titles in this collection

CADTH Common Drug Reviews

Recent Activity

Clear Turn Off Turn On

Table 1, Cost Comparison Table of Biologic Treatments for Rheumatoid Arthritis i...
Table 1, Cost Comparison Table of Biologic Treatments for Rheumatoid Arthritis in Adult Patients - Pharmacoeconomic Review Report: sarilumab (Kevzara)

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on